FDA-Approved vs. Compounded vs. Research Peptides

If you have looked at peptide therapy options online, you have probably encountered three different categories of peptide products: FDA-approved pharmaceuticals, compounded peptides, and research-only peptides. The distinctions among these categories have substantial implications for product quality, prescribing legitimacy, legal status, and what you actually receive when you obtain a peptide. They are also poorly understood by most patients and, in some cases, deliberately blurred by marketing.

This article explains what each category actually means, how to recognize which category a specific peptide falls into, and why the distinction should affect how you think about peptide therapy.

FDA-approved peptide pharmaceuticals

FDA-approved peptides are pharmaceutical products that have completed the formal FDA approval process. This typically requires Phase I, II, and III clinical trials demonstrating safety and efficacy for specific indications, manufacturing in FDA-inspected facilities, and ongoing post-market surveillance. Approval is granted for specific indications with specific prescribing information.

The peptide pharmaceutical market is large and growing. Familiar examples include semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), insulin and its analogs, oxytocin, leuprolide, octreotide, calcitonin, teriparatide, and dozens of others. These products have established prescribing pathways, insurance coverage in many cases, and substantial clinical evidence bases.

When prescribed for FDA-approved indications, these medications are reimbursed by insurance under varying coverage patterns. When prescribed off-label — for example, semaglutide for weight loss in a patient who does not meet the formal FDA criteria for Wegovy — coverage may not apply, but the medication itself is the same FDA-approved pharmaceutical.

The advantages of FDA-approved peptides are clear. Manufacturing quality is consistent. Identity and potency are guaranteed. The clinical evidence base supports the approved use. Adverse events are tracked through formal post-market surveillance.

The limitations are also clear. FDA-approved peptides are typically expensive when not insurance-covered. Some indications that may be appropriate are not FDA-approved (because no company has invested in the trials and approval process). And the FDA-approved label sometimes lags behind clinical practice and emerging evidence.

Compounded peptides

Compounded peptides are prepared by licensed compounding pharmacies for individual patients on physician prescription. Compounding has a long and legitimate history in American medicine, dating back to a time when virtually all medications were prepared in pharmacies rather than mass-manufactured. Modern compounding fills several specific roles: preparing medications in concentrations or formulations not commercially available, providing access to medications during shortage situations, and dispensing certain peptides and other agents that are not commercially marketed.

Two regulatory frameworks govern modern compounding pharmacies in the US, established by the Drug Quality and Security Act of 2013:

503A pharmacies are traditional compounding pharmacies that prepare medications for individual patients with valid prescriptions. They are regulated primarily by state pharmacy boards. Their products are intended for individual patient use and cannot be marketed broadly.

503B outsourcing facilities are larger operations that compound medications in bulk and can ship to healthcare facilities. They register with the FDA, follow current Good Manufacturing Practice (cGMP) standards, and undergo FDA inspections. Their compliance standards are more rigorous than 503A pharmacies.

Compounded peptides are legitimate when prescribed by licensed physicians and dispensed by licensed compounding pharmacies for individual patients with documented clinical indications. Common compounded peptides include BPC-157, TB-500, sermorelin, ipamorelin, CJC-1295, thymosin alpha-1, GHK-Cu, and many others.

Quality varies. The best compounding pharmacies follow rigorous standards and produce products that match prescribed specifications consistently. Less rigorous operations may produce variable products. Patients receiving compounded peptides should know which pharmacy is filling the prescription and should ask their physician about the pharmacy’s quality standards.

An important nuance: when a compounded peptide is essentially a copy of a commercially available FDA-approved drug, FDA rules generally restrict compounding to specific situations such as drug shortages or individualized formulations. The recent semaglutide and tirzepatide compounding situation has been complicated by exactly these rules — when the brand-name drugs were on FDA shortage lists, compounded versions were broadly permitted; as shortages resolved, the regulatory landscape changed.

Research peptides

Research peptides are sold for laboratory research use only. They are not legally available for human consumption in the United States. The most reliable indicator that a peptide is being marketed as a research compound is the disclaimer “for research purposes only, not for human consumption” — usually in small print at the bottom of websites that otherwise market the product as if it were a therapeutic.

Research peptide vendors operate in a legal gray area. The peptides themselves may be chemically identical to compounded versions, but the production standards, identity verification, and contamination controls are not held to pharmaceutical standards. Vendors who sell peptides as “research compounds” are explicitly disclaiming any intended use for human treatment, which exempts them from pharmaceutical regulation but also means that what arrives in the bottle may not be what is on the label.

Independent testing has documented significant problems with research peptide products: variable purity, mislabeled identity, undisclosed contaminants, and in some cases compounds entirely different from what was advertised. The “research only” disclaimer is the warning sign — these are not pharmaceutical products and are not subject to pharmaceutical quality control.

The Tide does not work with research peptides. We work exclusively with FDA-approved pharmaceuticals and licensed compounding pharmacies that meet specific quality standards. Patients who have obtained peptides from research sources before seeing us are advised to discontinue those products before starting clinical care.

How to tell which category a peptide is in

Some quick tests to identify the category:

If it has a brand name and FDA labeling (Ozempic, Mounjaro, Lupron, Vyleesi), it is an FDA-approved pharmaceutical.

If a clinic is dispensing it through a compounding pharmacy with a prescription, it is compounded. Reputable clinics will tell you which pharmacy fills your prescription and why they chose that pharmacy.

If you are buying it online from a website that includes “for research purposes only” anywhere on the page, it is a research product. The disclaimer exists for legal reasons; it is also an accurate description of what the product is.

If the website looks like a legitimate clinical site but uses unusual language like “we ship discreetly” or “no prescription required” or emphasizes “purity testing” without naming the testing standards, treat it with extreme caution.

Why the category matters for your care

The regulatory category affects several practical aspects of peptide therapy:

Quality and consistency. FDA-approved products and high-quality compounded preparations are reliable. Research products are not.

Legal and licensing implications. Physicians prescribing FDA-approved or properly compounded peptides operate within established regulatory frameworks. Physicians or patients using research peptides operate outside these frameworks.

Insurance coverage. Generally applies only to FDA-approved products for FDA-approved indications.

Adverse event tracking. Built-in for FDA-approved products. Less systematic for compounded products. Essentially nonexistent for research products.

What you are actually receiving. Reliable for FDA-approved and quality compounded products. Variable for research products.

The right questions to ask

If you are evaluating peptide therapy from any clinic, ask:

What specific peptide product are you prescribing, and what is its regulatory category? What pharmacy fills your prescriptions? What standards does that pharmacy follow? Is the peptide FDA-approved for any indication, or is it compounded? If compounded, what is the basis for compounding it (clinical justification, formulation needs, shortage status)?

A clinic that cannot answer these questions clearly is not operating with the regulatory and quality awareness that should accompany peptide prescribing. The questions are not adversarial; they are basic professional standards that legitimate practices welcome.

The peptide world includes legitimate FDA-approved pharmaceuticals, properly compounded products from quality compounding pharmacies, and a substantial gray market of research products that are not appropriate for clinical use. Knowing which category you are dealing with is the first step in making informed decisions about your care.